Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Researchers are looking for new ways to treat advanced solid tumors and von Hippel-Lindau (VHL)-related tumors: * Advanced means the cancer has spread to other parts of the body (metastatic) or cannot be removed with surgery * Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids * VHL-related tumors are tumors caused by VHL disease. VHL disease is passed down from parents to children and people with VHL disease have a higher chance of getting certain types of cancer Researchers want to learn about the long-term effects of a trial medicine called

Trial Details

NCT ID
NCT07405164
Phase
PHASE3
Sponsor
Merck Sharp & Dohme LLC
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Belzutifan
  • Palbociclib
  • Nivolumab
  • Lenvatinib
  • Cabozantinib
  • Everolimus
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Detroit, Michigan, United States|42.33143,-83.04575
  • San Antonio, Texas, United States|29.42412,-98.49363
  • Leuven, Vlaams-Brabant, Belgium|50.87959,4.70093

Key Eligibility Criteria

  • The main inclusion criteria include but are not limited to the following:
  • Participants with advanced solid tumors or von Hippel-Lindau-related neoplasms who are participating in belzutifan-containing studies and on active…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →